Press releases
- Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
- Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
- Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
- Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
- Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
- Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
- Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
- Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
- Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
- Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 101.50 |
---|---|
High | 101.50 |
Low | 101.50 |
Bid | 103.60 |
Offer | 104.05 |
Previous close | 101.50 |
Average volume | 9.89 |
---|---|
Shares outstanding | 62.35m |
Free float | 60.59m |
P/E (TTM) | 17.87 |
Market cap | 6.81bn USD |
EPS (TTM) | 6.12 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 07:03 BST.
More ▼